バセドウ病（甲状腺機能亢進症）の世界市場

バセドウ病（甲状腺機能亢進症）の世界市場は2030年までに4億8,710万米ドルに達する見込み

2024年に3億9,790万米ドルと推定されるバセドウ病（甲状腺機能亢進症）の世界市場は、2030年には4億8,710万米ドルに達し、分析期間2024-2030年のCAGRは3.4%で成長すると予測されます。本レポートで分析したセグメントの1つである抗甲状腺薬は、CAGR 3.7%を記録し、分析期間終了時には2億970万米ドルに達すると予測されます。β遮断薬セグメントの成長率は、分析期間中CAGR 3.0％と推定されます。

米国市場は1億840万米ドルと推定、中国はCAGR6.4％で成長予測

米国のバセドウ病（甲状腺機能亢進症）市場は、2024年に1億840万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに9,710万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.3％と2.7％と予測されています。欧州では、ドイツがCAGR 2.0%で成長すると予測されています。

バセドウ病（甲状腺機能亢進症）市場- 主要動向と促進要因のまとめ

バセドウ病が世界の公衆衛生上の懸念になりつつあるのはなぜか？

世界の甲状腺機能亢進症の主な原因であるバセドウ病は、その有病率の上昇、過小診断、代謝の健康への重大な影響のため、医療システムからの注目が高まっています。甲状腺刺激免疫グロブリン（TSI）による甲状腺ホルモンの過剰産生を特徴とするこの自己免疫疾患は、女性に偏って罹患し、しばしば30～50歳で発症します。治療可能ではあるが、管理せずに放置すると、心血管ストレス、骨粗鬆症、眼疾患（バセドウ病眼窩症）、不妊症などの深刻な合併症を引き起こす可能性があります。

自己免疫疾患の世界の増加は、遺伝的感受性、環境的誘因、生活習慣の変化によるもので、バセドウ病はさらに脚光を浴びています。甲状腺関連疾患、特に女性の健康に対する意識の高まりと、定期的な甲状腺機能検査も発見率の向上に寄与しています。公衆衛生機関は、特に自己免疫性甲状腺疾患が多い北米、欧州、アジアの一部で、甲状腺の健康を予防医療プログラムに含めるようになってきています。

疾患管理を改善するために、診断法と治療法はどのように進化しているのでしょうか？

甲状腺刺激ホルモン（TSH）測定法、放射性ヨード取り込み検査、抗甲状腺抗体プロファイリングの普及により、バセドウ病の診断状況は著しく改善しました。高解像度の甲状腺超音波検査や放射性核種スキャンなどの画像技術の革新により、現在ではより正確な病期分類や他の甲状腺機能亢進症との鑑別ができるようになりました。これにより、特に甲状腺結節や自己免疫疾患の併存が臨床像を複雑にしている場合、臨床医はタイムリーで的確な治療方針を決定できるようになりました。

バセドウ病の治療法は、抗甲状腺剤（メチマゾールやプロピルチオウラシルなど）、放射性ヨード治療（RAI）、甲状腺切除術の3つの主要な経路に沿って進化し続けています。それぞれの選択肢は、年齢、病気の重症度、妊娠の状態、併存疾患を含む患者固有の因子に基づいて選択されます。最近の研究では、特に肝毒性と無顆粒球症のリスクに関して、抗甲状腺薬の長期的な安全性と忍容性を改善することに焦点が当てられています。これと並行して、低侵襲甲状腺手術や放射性ヨウ素の標的投与法の進歩により、合併症が減少し、治療後のQOLが向上しています。現在研究中の新しい治療法には、TSHレセプター抗体を標的とした生物学的製剤や、症状を抑えるだけでなく病気の経過を変えることを目的とした免疫調節剤などがあります。

市場需要を形成している地域と患者層は？

バセドウ病は地域によって有病率や管理パターンが異なります。北米は、高いヘルスケア支出、確立された内分泌学ネットワーク、市民意識向上キャンペーンに支えられ、診断と治療へのアクセスという点で市場をリードしています。欧州は、英国やドイツのような国々が強固なスクリーニング・プログラムや包括的な自己免疫疾患管理枠組みを有していることから、その後に続いています。アジア太平洋地域では、ヘルスケアのインフラが整備され、都市部の意識が高まっていることが診断率の向上に寄与しているが、農村部の人口が多いため、内分泌専門医へのアクセスは限られています。

人口統計学的に、バセドウ病と診断された症例の75％以上が女性であり、特に生殖期には女性の健康診断と研究に重点が置かれています。バセドウ病はまた、思春期や更年期の女性にも発症することが多くなっており、診断や治療の複雑さが増しています。さらに、甲状腺眼症の場合、長期的なモニタリングと眼科的サポートに対する需要が、専門医療におけるサポート診断と外科的介入のための二次市場を生み出しています。

バセドウ病市場の成長はいくつかの要因に牽引されている...

バセドウ病市場の成長は、治療プロトコルの進化、診断の革新、内分泌学的治療へのアクセスの拡大に直接結びつくいくつかの要因によって牽引されています。技術的には、より高感度な免疫測定法、精緻な画像診断ツール、コンパニオン診断キットの開発により、疾患の検出とモニタリング能力が大幅に向上しています。これらの進歩により、リスクを最小限に抑え、長期的な転帰を向上させる個別化治療戦略が可能になりました。

最終用途の面では、自己免疫性甲状腺疾患の負担の増加に加えて、一般市民の意識の高まりと定期的なスクリーニングの実施により、治療対象が拡大しています。内分泌学、眼科、外科の専門知識を組み合わせた統合甲状腺医療モデルの出現は、高度医療サービスの需要をさらに押し上げています。さらに、新興国におけるヘルスケア支出の増加と遠隔内分泌学プラットフォームの成長により、以前は十分なサービスが受けられなかった地域でのケアへのアクセスが向上しています。免疫療法や疾患修飾薬に焦点を当てた臨床試験が進行中であり、バセドウ病治療市場の世界の継続的拡大を示唆する革新的な治療環境が整いつつあります。

セグメント

治療薬（抗甲状腺薬、ベータ遮断薬、ヨード療法、放射性ヨード療法、その他の治療薬）;投与経路（経口、非経口、その他の投与経路）;流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の47社）

• Abbott Laboratories
• Apitope International NV
• bioMerieux SA
• Crinetics Pharmaceuticals
• F. Hoffmann-La Roche Ltd
• HanAll Biopharma
• Horizon Therapeutics（Amgen Inc.）
• Immunovant, Inc.
• Institute of Isotopes Co., Ltd.
• Jubilant Pharma Holdings Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Sanofi
• Sling Therapeutics
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Thermo Fisher Scientific Inc.
• Tourmaline Bio
• Viridian Therapeutics

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Graves' Disease (Overactive Thyroid) Market to Reach US$487.1 Million by 2030

The global market for Graves' Disease (Overactive Thyroid) estimated at US$397.9 Million in the year 2024, is expected to reach US$487.1 Million by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Anti-thyroid Drugs, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$209.7 Million by the end of the analysis period. Growth in the Beta Blockers segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$108.4 Million While China is Forecast to Grow at 6.4% CAGR

The Graves' Disease (Overactive Thyroid) market in the U.S. is estimated at US$108.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$97.1 Million by the year 2030 trailing a CAGR of 6.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Graves' Disease (Overactive Thyroid) Market - Key Trends & Drivers Summarized

Why Is Graves' Disease Emerging as a Global Public Health Concern?

Graves' disease, the leading cause of hyperthyroidism worldwide, is gaining increasing attention from health systems due to its rising prevalence, underdiagnosis, and its significant impact on metabolic health. This autoimmune disorder, characterized by excessive thyroid hormone production due to thyroid-stimulating immunoglobulins (TSIs), disproportionately affects women and often manifests in individuals aged 30 to 50. Although treatable, if left unmanaged, it can lead to serious complications, including cardiovascular stress, osteoporosis, eye disease (Graves' orbitopathy), and fertility issues.

The global increase in autoimmune diseases, driven by genetic susceptibility, environmental triggers, and lifestyle changes, has pushed Graves' disease further into the spotlight. A heightened awareness of thyroid-related disorders, especially in women’s health, and routine thyroid function testing have also contributed to higher detection rates. Public health agencies are increasingly including thyroid health in their preventive care programs, particularly in North America, Europe, and parts of Asia where autoimmune thyroid conditions are more prevalent.

How Are Diagnostics and Treatment Modalities Evolving to Improve Disease Management?

The diagnostic landscape for Graves' disease has significantly improved, driven by the widespread availability of thyroid-stimulating hormone (TSH) assays, radioactive iodine uptake tests, and anti-thyroid antibody profiling. Innovations in imaging technology, such as high-resolution thyroid ultrasound and radionuclide scanning, now allow for more accurate disease staging and differentiation from other forms of hyperthyroidism. This has enabled clinicians to make timely and precise treatment decisions, especially in cases where thyroid nodules or coexisting autoimmune conditions complicate the clinical picture.

Treatment approaches for Graves' disease continue to evolve along three primary paths: antithyroid medications (like methimazole and propylthiouracil), radioactive iodine therapy (RAI), and thyroidectomy. Each option is selected based on patient-specific factors including age, disease severity, pregnancy status, and comorbidities. Recent studies have focused on improving the long-term safety and tolerability of antithyroid drugs, particularly regarding hepatotoxicity and agranulocytosis risks. In parallel, advancements in minimally invasive thyroid surgeries and targeted radioiodine dosing have reduced complications and improved post-treatment quality of life. Novel therapies under investigation include biologics targeting TSH receptor antibodies and immune modulators aimed at altering the disease course rather than just controlling symptoms.

Which Regions and Patient Demographics Are Shaping Market Demand?

Graves' disease exhibits varying prevalence and management patterns across regions. North America leads the market in terms of diagnosis and treatment accessibility, supported by high healthcare expenditure, established endocrinology networks, and public awareness campaigns. Europe follows closely, where countries like the UK and Germany have robust screening programs and comprehensive autoimmune disease management frameworks. In the Asia-Pacific region, rising healthcare infrastructure and increasing urban awareness are contributing to improved diagnosis rates, although large rural populations still face underdiagnosis and limited access to endocrine specialists.

Demographically, women account for over 75% of all diagnosed cases of Graves’ disease, particularly during reproductive years, prompting focused efforts in women's health screening and research. The condition is also increasingly observed in adolescents and perimenopausal women, creating additional layers of diagnostic and therapeutic complexity. Furthermore, the demand for long-term monitoring and ophthalmologic support in cases of thyroid eye disease is creating secondary markets for supportive diagnostics and surgical interventions in specialty care.

The Growth in the Graves’ Disease Market Is Driven by Several Factors…

The growth in the Graves’ disease market is driven by several factors directly tied to evolving treatment protocols, diagnostic innovation, and expanding access to endocrinological care. Technologically, the development of more sensitive immunoassays, refined imaging tools, and companion diagnostic kits has significantly improved disease detection and monitoring capabilities. These advancements enable personalized treatment strategies that minimize risks and enhance long-term outcomes.

On the end-use front, the increasing burden of autoimmune thyroid diseases, along with heightened public awareness and routine screening practices, is expanding the treatment population. The emergence of integrated thyroid care models-combining endocrinology, ophthalmology, and surgical expertise-is further boosting demand for advanced care services. Additionally, rising healthcare expenditure in emerging economies and the growth of tele-endocrinology platforms are improving access to care in previously underserved regions. With ongoing clinical trials focused on immunotherapies and disease-modifying drugs, the therapeutic landscape is poised for innovation, signaling continued expansion of the Graves’ disease treatment market globally.

SCOPE OF STUDY:

The report analyzes the Graves' Disease (Overactive Thyroid) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy, Other Treatments); Administration Route (Oral, Parenteral, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• Abbott Laboratories
• Apitope International NV
• bioMerieux SA
• Crinetics Pharmaceuticals
• F. Hoffmann-La Roche Ltd
• HanAll Biopharma
• Horizon Therapeutics (Amgen Inc.)
• Immunovant, Inc.
• Institute of Isotopes Co., Ltd.
• Jubilant Pharma Holdings Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Sanofi
• Sling Therapeutics
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Thermo Fisher Scientific Inc.
• Tourmaline Bio
• Viridian Therapeutics

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Graves' Disease (Overactive Thyroid) - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Autoimmune Disorders Propels Demand for Graves Disease Diagnosis and Treatment
  • Increased Awareness and Early Screening Programs Expand the Addressable Patient Base
  • Advancements in Diagnostic Imaging and Antibody Testing Drive Adoption of Precision Diagnostics
  • Growth in Thyroid Function Test Utilization Enhances Early Detection Rates for Graves Disease
  • Development of Targeted Therapies and Biologics Strengthens the Treatment Pipeline
  • Expansion of Telehealth and Endocrinology Consultations Accelerates Diagnosis in Underserved Areas
  • Patient Education Initiatives Throw the Spotlight on Symptom Recognition and Early Intervention
  • Growing Geriatric Population Increases Prevalence of Thyroid Dysfunctions and Treatment Demand
  • Innovation in Radioactive Iodine Therapy and Dosimetry Improves Patient Outcomes and Safety
  • Surgical Advancements and Minimally Invasive Techniques Drive Treatment Option Expansion
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Graves' Disease (Overactive Thyroid) Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Graves' Disease (Overactive Thyroid) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Anti-thyroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Anti-thyroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Anti-thyroid Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Beta Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Iodine Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Iodine Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Iodine Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Radioactive Iodine Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Radioactive Iodine Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Radioactive Iodine Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• JAPAN
  • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• CHINA
  • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• EUROPE
  • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Graves' Disease (Overactive Thyroid) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• FRANCE
  • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• GERMANY
  • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Graves' Disease (Overactive Thyroid) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• INDIA
  • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Graves' Disease (Overactive Thyroid) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Graves' Disease (Overactive Thyroid) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
• AFRICA
  • Graves' Disease (Overactive Thyroid) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Graves' Disease (Overactive Thyroid) by Treatment - Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Treatment - Percentage Breakdown of Value Sales for Anti-thyroid Drugs, Beta Blockers, Iodine Therapy, Radioactive Iodine Therapy and Other Treatments for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Graves' Disease (Overactive Thyroid) by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Graves' Disease (Overactive Thyroid) by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Graves' Disease (Overactive Thyroid) by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030

IV. COMPETITION